| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 02/27/2003 | CA2456868A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | CA2456820A1 Physiological method of improving vision |
| 02/27/2003 | CA2455120A1 Method and intra sclera implant for treatment of glaucoma and presbyopia |
| 02/27/2003 | CA2453647A1 1-alkyl 0r 1-cycloalkyltriazolo¬4,3-a|quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | WO2002020467A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)-[n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient |
| 02/26/2003 | EP1285922A1 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | EP1285657A2 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| 02/26/2003 | EP1285063A1 Anti-angiogenic polypeptides |
| 02/26/2003 | EP1284988A1 Laminin 15 and uses thereof |
| 02/26/2003 | EP1284977A1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 02/26/2003 | EP1284974A2 Triazolyl tropane derivatives as ccr5 modulators |
| 02/26/2003 | EP1284973A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 02/26/2003 | EP1284959A1 Compounds for modulating the rage receptor |
| 02/26/2003 | EP1284717A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 02/26/2003 | EP1284698A1 Method of pre-selecting a polymerizable fluid formed into an intraocular lens |
| 02/26/2003 | EP1150976B1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 02/26/2003 | EP1100797B1 Heterocyclic compounds as inhibitors of rotamase enzymes |
| 02/26/2003 | EP1042297B1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/26/2003 | EP0929571B1 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 02/26/2003 | EP0732913B1 SYNTHETIC VISCOELASTIC MATERIAL for physiological applications such as FOR OPHTHALMIC APPLICATIONs |
| 02/26/2003 | CN1399633A 嘧啶衍生物 Pyrimidine derivatives |
| 02/26/2003 | CN1399552A Method and composition for treatment of adenoviral ocular infections |
| 02/26/2003 | CN1399548A Composition for treatment of external secretion disorders |
| 02/26/2003 | CN1399547A Use of INOS inhibitors for treating or preventing myopia |
| 02/26/2003 | CA2419744A1 A novel crystal of n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)-¬n-(4-phenoxyphenylcarbonyl)amino|pentanamide and a method for the preparation thereof and a pharmaceutical agent comprising the same as active ingredient |
| 02/25/2003 | US6525202 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 02/25/2003 | US6525083 Antidiabetic agents, antilipemic agents, anticholesterol agents |
| 02/25/2003 | US6525070 Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists |
| 02/25/2003 | US6525055 Allergic and inflammatory pathologies such as, for example, emphysema, chronic bronchitis, asthma and allergic rhinitis. |
| 02/25/2003 | US6525040 4,4-dimethyl-thieno-(3,2-e)-isoselenazine; antioxidants and cytoprotecting |
| 02/25/2003 | US6525019 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 02/25/2003 | US6524813 Novel polynucleotides and polypeptides of the spo0J family derived from Staphylococcus |
| 02/25/2003 | US6524583 Inhibit angiogenesis and induce tumor regression, and have improved safety due to their specificity |
| 02/25/2003 | US6524581 Integrin or integrin subunit antagonist, leukocyte adhesion-inducing cytokine antagonist or growth factor antagonist, a selectin antagonist or adhesion molecule antagonist. |
| 02/25/2003 | CA2104868C Method and products for treating the eye |
| 02/21/2003 | WO2002020462A1 Benzoic acid derivatives and drugs containing the same as the active ingredient |
| 02/21/2003 | WO2002016328A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | WO2002016323A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | CA2420208A1 Biphenyl derivatives and their use as integrin inhibitors |
| 02/21/2003 | CA2420205A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | CA2419722A1 Benzoic acid derivatives and drugs containing the same as the active ingredient |
| 02/20/2003 | WO2003014315A2 Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| 02/20/2003 | WO2003014294A2 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | WO2003014124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 02/20/2003 | WO2003014101A1 Hydroxamic acid derivatives |
| 02/20/2003 | WO2003014098A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 02/20/2003 | WO2003014092A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 02/20/2003 | WO2003014083A1 Spiro compounds |
| 02/20/2003 | WO2003013655A2 Carbonic anhydrase inhibitors |
| 02/20/2003 | WO2003013612A1 Polysaccharide-containing compositions and use thereof |
| 02/20/2003 | WO2003013556A1 Medicinal compositions having effects of ameliorating eye diseases and holding eye functions |
| 02/20/2003 | WO2003013545A1 Novel benzo-fused heterocycles as endothelin antagonisits |
| 02/20/2003 | WO2003013530A2 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists |
| 02/20/2003 | WO2003013522A1 Preventives/remedies for cholinergic neuropathy |
| 02/20/2003 | WO2003013513A1 Stable emulsion composition |
| 02/20/2003 | WO2003013511A1 Integrin inhibitors for the treatment of eye diseases |
| 02/20/2003 | WO2003013487A2 Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field |
| 02/20/2003 | WO2003013477A1 Drug release system for controlled therapy |
| 02/20/2003 | WO2003013434A2 Methods and compositions for treating diseases associated with excesses in ace |
| 02/20/2003 | WO2003013432A2 Methods of use for novel sulfur containing organic nitrate compounds |
| 02/20/2003 | WO2003013427A2 A method for preparing fluticasone derivatives |
| 02/20/2003 | WO2003013424A2 Use of r-nsaid compounds for anti-hiv treatment |
| 02/20/2003 | WO2002100858A3 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors |
| 02/20/2003 | WO2002096927A3 Ribozyme based treatment of female reproductive diseases |
| 02/20/2003 | WO2002089815A3 Disinfecting and solubilizing steroid compositions |
| 02/20/2003 | WO2002078564A3 Method for creating a separation of posterior cortical vitreous from the retina of the eye |
| 02/20/2003 | WO2002072585A3 Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 02/20/2003 | WO2002072003A3 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 02/20/2003 | WO2002064126A3 Method of treating of demyelinating diseases or conditions |
| 02/20/2003 | WO2002008268A3 Leucine-based motif and clostridial neurotoxins |
| 02/20/2003 | WO2001064949A9 Diagnostics and therapeutics for glaucoma |
| 02/20/2003 | US20030036545 (6-aryl-pyrrolo(2,3-d)pyrimidin-4-yl)amine derivatives; treating Parkinson's disease and diseases associated with locomotor activity, vasodilation, platelet inhibition, neutrophil superoxide generation, cognitive disorders, etc. |
| 02/20/2003 | US20030036535 Physiological method of improving vision |
| 02/20/2003 | US20030036534 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 02/20/2003 | US20030035787 Polyanhydrides with biologically active degradation products |
| 02/20/2003 | CA2701551A1 Polysaccharide-containing compositions and use thereof |
| 02/20/2003 | CA2456939A1 Carbonic anhydrase inhibitors |
| 02/20/2003 | CA2456833A1 Polysaccharide-containing compositions and use thereof |
| 02/20/2003 | CA2456706A1 Drug release system for controlled therapy |
| 02/20/2003 | CA2456599A1 Spiro compounds |
| 02/20/2003 | CA2456594A1 Preventives/remedies for cholinergic neuropathy |
| 02/20/2003 | CA2456291A1 Hydroxamic acid derivatives |
| 02/20/2003 | CA2456124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 02/20/2003 | CA2456103A1 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives |
| 02/20/2003 | CA2454417A1 Novel benzo-fused heterocycles as endothelin antagonists |
| 02/20/2003 | CA2453995A1 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | CA2453433A1 Methods of use for novel sulfur containing organic nitrate compounds |
| 02/20/2003 | CA2451691A1 Use of r-nsaid compounds for anti-hiv treatment |
| 02/19/2003 | EP1284143A1 A process for the preparation of pharmaceutical formulations containing lactoferrin description |
| 02/19/2003 | EP1283886A2 Intracellular signaling proteins |
| 02/19/2003 | EP1283834A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283833A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283832A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283831A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283828A1 Novel polymorph v of torasemide |
| 02/19/2003 | EP1283827A2 Caspase inhibitors and uses thereof |
| 02/19/2003 | EP1283672A1 Antitubulin assembly and cell growth inhibitor denominated "dioxostatin" |
| 02/19/2003 | EP1133491B1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same |
| 02/19/2003 | EP1119571B1 Tricyclic delta3-piperidines as alpha2-antagonists |
| 02/19/2003 | EP1087777B1 Therapeutic dinucleotide and derivatives |